Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7156 to 7170 of 7707 results

  1. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

    This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.

    Technology appraisal guidance
    Published
    9 August 2017

  2. Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

    This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Technology appraisal guidance
    Published
    23 August 2017

  3. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

    We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.

    Technology appraisal guidance
    Published
    30 August 2017

  4. Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

    This guidance has been updated and replaced by NICE technology appraisal guidance 629.

    Technology appraisal guidance
    Published
    30 August 2017

  5. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (TA48)

    This guidance has been updated and replaced by NICE guideline NG107 

    Technology appraisal guidance
    Published
    26 September 2002

  6. Ischaemic heart disease - coronary artery stents (TA4)

    This guidance has been replaced by NICE technology appraisal guidance 71. 

    Technology appraisal guidance
    Published
    27 May 2000

  7. The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)

    This guidance has been updated and replaced by NICE technology appraisal guidance 187.

    Technology appraisal guidance
    Published
    26 April 2002

  8. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Technology appraisal guidance
    Published
    26 June 2002

  9. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

    Technology appraisal guidance
    Published
    25 January 2017

  10. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    This guidance has been updated and replaced by NICE technology appraisal guidance 752.

    Technology appraisal guidance
    Published
    22 June 2016

  11. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

    Technology appraisal guidance
    Published
    19 July 2017

  12. Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

    We have withdrawn the guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.

    Technology appraisal guidance
    Published
    26 July 2017

  13. Guidance on the use of metal on metal hip resurfacing arthroplasty (TA44)

    This guidance has been updated and replaced by NICE technology appraisal guidance 304.

    Technology appraisal guidance
    Published
    26 June 2002

  14. Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)

    This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.

    Technology appraisal guidance
    Published
    26 April 2017

  15. Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 674. People already taking pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their doctor decide when best to stop.

    Technology appraisal guidance
    Published
    13 June 2018